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Background: There is considerable interest in inducing RNA interference (RNAi) in neurons to study gene function
and identify new targets for disease intervention. Although short interfering RNAs (siRNAs) have been used to
silence genes in neurons, in vivo delivery of RNAi remains a major challenge, especially by systemic administration.
We have developed a highly efficient method for in vivo gene silencing in dorsal root ganglia (DRG) by using short
hairpin RNA–expressing single-stranded adeno-associated virus 9 (ssAAV9-shRNA).
Results: Intraperitoneal administration of ssAAV9-shRNA to neonatal mice resulted in highly effective and specific
silencing of a target gene in DRG. We observed an approximately 80% reduction in target mRNA in the DRG, and
74.7% suppression of the protein was confirmed by Western blot analysis. There were no major side effects, and the
suppression effect lasted for more than three months after the injection of ssAAV9-shRNA.
Conclusions: Although we previously showed substantial inhibition of target gene expression in DRG via
intrathecal ssAAV9-shRNA administration, here we succeeded in inhibiting target gene expression in DRG neurons
via intraperitoneal injection of ssAAV9-shRNA. AAV9-mediated delivery of shRNA will pave the way for creating
animal models for investigating the molecular biology of the mechanisms of pain and sensory ganglionopathies.
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Dorsal root ganglia (DRG) are nodules that contain the
cell bodies of primary sensory neurons, which send out
afferent axons and convey sensory information from the
periphery to the spinal cord. The loss of sensory neurons
in DRG causes the degeneration of peripheral axons and
central sensory projections in the posterior columns.
Dysfunction of small DRG neurons may cause intrac-
table sensory symptoms, including severe pain and
allodynia, and that of large neurons may cause motor
symptoms due to sensory ataxia.
To investigate the mechanisms of pain and systemic sen-
sory neuronopathies, it is necessary to establish methods* Correspondence: tak-yokota.nuro@tmd.ac.jp
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reproduction in any medium, provided the orother than knockout mouse techniques to postnatally
regulate genes in the DRG, because genetic deletion of
endogenous DRG genes may cause compensatory modula-
tion of other genes during developmental or lead to embry-
onic lethality in mice [1].
RNA interference (RNAi) has emerged as a powerful
tool to induce loss-of-function phenotypes through the
post-transcriptional silencing of gene expression [2,3],
not only because of its potential application in functional
genomic studies and target validation, but also because
of its potential use as a therapeutic strategy to silence
disease-causing genes. The RNAi pathway is initiated by
the Dicer enzyme, which cleaves long, double-stranded
RNAs into short (21- to 23-nucleotide) interfering RNAs
(siRNAs) that mediate sequence-specific gene silencing
[4,5]. siRNAs can also be derived from short hairpin
RNAs (shRNA) expressed from a viral vector [6].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Constructions of ssAAV9-GFP and ssAAV9-shSOD1
vector. CMV = cytomegalovirus, hrGFP = humanized Renilla Green
Fluorescent Protein, hGH poly A = human growth hormone
polyadenylation, L-ITR and R ITR = left and right inverted terminal
repeats, respectively.
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tool for delivering genes into the central nervous system
(CNS) because of their ability to infect post-mitotic
neurons and mediate efficient and stable transduction
with little immunogenicity or toxicity [7,8]. A number of
serotypes have been identified, which have varying
efficiency and tropism [9,10]. Ourselves and another
group have reported that, when administered intra-
thecally, AAV5 and AAV9 are efficient vehicles to deliver
siRNA to DRG neurons [11,12]. Zheng et al. demon-
strated that AAV8 is effective in retrograde transport
from muscle to spinal cord and DRG [13]. Foust et al.
reported that a single intravenous injection of self-
complementary AAV9 into newborn mice provided gene
transfer across the blood–brain barrier (BBB) and into
the CNS [14]. Subsequently, other researchers have
reported that intravenous administration of single-
stranded AAV9 vector can deliver a target gene with
extensive CNS expression [15,16]. However, all of these
past reports are related to the expression of a reporter
or functional protein; there have been no reports
demonstrating silencing of a target gene in the nervous
system via intraperitoneal injection.
In the present study, we injected single-stranded
AAV9-shRNA (ssAAV9-shRNA) intraperitoneally to
neonatal mice and sufficiently inhibited a target gene in
the DRG without any side effects. We chose superoxide
dismutase 1 (SOD1) as the target gene because it is an
appropriate endogenous gene for evaluating the side
effects associated with both shRNA and AAV adminis-
tration. SOD1 is ubiquitously expressed in the CNS, and
SOD1-knockout mice exhibit no obvious neurological
phenotypes [17,18].
Results
Efficient transfer of GFP to DRG after intraperitoneal
administration of ssAAV9 vector
To investigate whether AAV9 vector can transfer a gene
to DRG, we intraperitoneally injected neonatal mice with
ssAAV9 vector encoding green fluorescent protein
(ssAAV9-GFP, Figure 1). Four weeks after the injection,
the mice were euthanized, and GFP expression in the
DRG was assessed. We detected efficient GFP expression
in the DRG (Figure 2), indicating that the ssAAV9 vector
can deliver the GFP gene to the DRG. In the CNS, GFP
expression was not detected except in the posterior
column and posterior horn, into which the axons of the
DRG neurons project (Additional file 1: Figure S1).
SOD1 mRNA and protein expression in DRG after
intraperitoneal administration of anti-SOD1 ssAAV9-
shRNA (ssAAV9-shSOD1)
We next intraperitoneally injected neonatal mice with
ssAAV9-shSOD1 vector to determine its ability to suppressthe expression of SOD1 in DRG (Figure 1). Four weeks
after injection, SOD1 expression in the DRG was assessed
by quantitative RT-PCR (qRT-PCR). In order to evaluate
the reduction level of SOD1, we used the DRG of ssAAV9-
GFP injected mice as a control. The expression level of
SOD1 mRNA in the DRG of injected mice was about 80%
lower than that of controls (Figure 3A) and lasted for at
least 12 weeks (Figure 3B). We did not detect any SOD1
silencing in the spinal cord (Figure 3C). The knockdown
effect was specific for the target gene (SOD1), given that
the levels of other endogenous mRNAs—those encoding
GAPDH, hypoxanthine-guanine phosphoribosyltransferase,
and β-tubulin—did not change (data not shown), sug-
gesting that ssAAV9-shSOD1 did not affect the expression
of unrelated endogenous genes. Western blot analysis
confirmed decreased SOD1 levels in the DRG of the mice
injected with ssAAV9-shSOD1 (Figure 4A). Compared
with that in control mice, the mean level of SOD1 expres-
sion in anti-SOD1 mice was 74.7% and 69.6% lower after 4
and 12 weeks, respectively (Figure 4B).
Histological evaluation of DRG
We histologically evaluated whether any anatomical
abnormalities occurred in the DRG after ssAAV9-sh
SOD1 injection. Hematoxylin and eosin and Nissl stain-
ing of the DRG showed no inflammatory, necrotic, or
degenerative lesions (Figure 5A, B). In order to confirm
the neuroinflammation, we performed the following im-
munohistochemical staining; Iba1 (Figure 5C) for micro-
glial activation and CD68 (Figure 5D) for macrophage
invasion. Although we detected the slight microglial
activation and macrophage invasion, there was no
deference between AAV9-shSOD1 and control.
Figure 2 Efficient gene transfer to DRG after neonatal intraperitoneal delivery. Identification of efficient GFP expression in DRG 4 weeks
after intraperitoneal injection of ssAAV9-GFP vector. Scale bars: 100 μm.
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To assess their general health and the motor and
sensory functions of their hind limbs, we observed the
mice at 4 and 12 weeks after injection with ssAAV9-sh
SOD1. Body weights of the mice in the ssAAV9-sh
SOD1–injected group were similar to those in the
control group (Figure 6A). Importantly, there were no
significant differences between the groups at 4 andFigure 3 Silencing effect of ssAAV9-shSOD1 vector on mRNA express
and 12 weeks (B) after injection with ssAAV9-shRNA vector shows that sup
(*P < 0.05). There is no significant difference of the expression level of SOD112 weeks after injection, according to tactile (Figure 6B)
and acetone (Figure 6C) tests. Furthermore, accelerating
rotarod tests revealed no significant differences in motor
function between controls and ssAAV9-shSOD1–
injected mice (Figure 6D). We previously reported that
the serum aspartate aminotransferase, alanine amino-
transferase, alkaline phosphatase, lactate dehydrogenase,
creatine kinase, total protein, and albumin values areion level of SOD1. The qRT-PCR of SOD1 mRNA in DRG at 4 weeks (A)
eroxide dismutase-1 (SOD1) expression was significantly inhibited
mRNA between ssAAV9-shSOD1 and control in the spinal cord (C).
Figure 4 Silencing effect of ssAAV9-shSOD1 vector on protein level of SOD1. The SOD1 protein level was reduced in DRG as assessed by
Western blot analysis at 4 weeks and 12 weeks after injection (A). Densitometric analysis of Western blot bands confirmed significant
downregulation of SOD1 in the injected mice at both 4 and 12 weeks (B). Data are presented as mean ± SEM (*P < 0.05, n = 7 for each group).
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strate that the injected mice grow and develop without
any side effects from the ssAAV9-shSOD1 vector.
Discussion
We report that a single intraperitoneal injection of
ssAAV9-shSOD1 inhibits SOD1 expression in neonatal
DRG without any adverse effects. Although the success-
ful delivery of reporter genes (e.g., GFP and LacZ) and
functional genes encoding therapeutic or pathogenic
proteins (e.g., Survival of Motor Neuron, prepro-β-en-
dorphin a, TAR DNA-binding protein 43) have been
reported previously [13-16,20,21], our current data are
the first to show sufficient inhibition of a target gene in
neurons after a single intraperitoneal administration of
vector-mediated delivery of shRNA. In previous reports,
gene knockdown in DRG was achieved by direct injec-
tion into these structures [22] or by retrograde transportafter sciatic nerve injection [23]. Recently, we and
another group showed efficient gene knockdown in
DRG after intrathecal delivery [11,12]. These approaches
enable viral vectors to bypass the blood–nerve barrier
(BNB) and are therefore suitable for silencing the DRG
neurons local to where the vectors are injected. How-
ever, to utilize gene delivery methods in pain research,
frequent and multiple injections are needed to transduce
DRG neurons throughout the whole body, practice that
leads to increased viral load and risk of an immune
response [24]. In contrast, intraperitoneal delivery
methods provide extensive and global inhibition of the
target gene in all DRG neurons through a simple pro-
cedure. In this respect, the simplicity of intraperitoneal
injection makes the technique superior for inducing
RNAi in DRG neurons throughout the whole body.
In this study, we inhibited target gene expression in
neonatal DRG neurons despite the known hepatotropism
Figure 5 Pathological examination of DRG. Photomicrographs of hematoxylin and eosin staining (A), Nissl staining (B), Iba1 (C) and CD68 (D)
immunohistochemical staining of DRG neurons from ssAAV9-shSOD1–injected mice showed no differences between ssAAV9-shSOD1 and control
(scale bars: 20 μm).
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Although it is ultimately desirable to minimize target gene
expression in adult mice, administration of high doses of
AAV vectors interferes with endogenous microRNA
processing, causing microRNA saturation and ultimately
fatal liver toxicity because of the hepatotropism of AAV
[25]. In the case of neonates, however, expression of
shRNA in the liver is followed by rapid dilution of the
shRNA during liver growth and hepatocyte division
[26,27]. We previously demonstrated low reduction of
target gene expression in neonatal liver by intraperitoneal
injection of ssAAV9-shRNA [19], a finding that indicates
that shRNA-induced silencing has different features individing compared with non-dividing cells and that
neonatal DRG are a suitable target for intraperitoneally
administered AAV9-shRNA.
Using intraperitoneal administration, we successfully
bypassed the BNB and delivered ssAAV9-shSOD1 vector
to DRG. The BNB is formed by the tight junctions
between the endothelial cells of capillaries, and it
restricts the transport and diffusion of solutes from
blood to nerves [28-30]. We consider the following three
possible routes for AAV9 to cross the BNB: (1) AAV9
directly crosses the BNB and reaches the DRG. Some
evidence suggests that the barrier function of the BNB is
especially vulnerable during the neonatal period, when
Figure 6 Sensory and locomotive function and growth of the mice. At 4 weeks and 12 weeks, none of the ssAAV9-shSOD1–injected mice
showed any significant differences in body weight compared with controls (A). Similarly, in the von Frey test (B) and acetone test (C), none of
the injected mice showed significant differences in sensory function compared with controls. In the accelerating rotarod test, all of the injected
mice could perform the task similar to that of the controls (D). Each mouse was examined in 4 trials each day (T1–T4), for 4 consecutive days
(D1–D4). There was no significant difference between the injected mice group and the control group. Data are presented as mean ± SEM
(n = 7 for each group, P < 0.05).
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ing to a loose BNB that might not give full protection
against toxins and antibodies [30]. Therefore, DRG exist
outside of the protection of the BNB and are exposed to
circulating solutes in the blood, including AAV vectors.
(2) AAV9 enters the ventricles across the blood–cere-
brospinal-fluid (CSF) barrier and is then distributed to
DRG by the circulating CSF. Miyake et al. demonstrated
that stronger GFP signals were detected in areas in
contact with the CSF after intravenous injection of
AAV9-GFP and suggested a promising mechanism by
which AAV9 vectors pass through the BBB [15]. Further-
more, the perineurium of the DRG has fewer layers of
perineurial cells and larger gaps than do peripheral
nerves [31]. (3) AAV9 are transported from muscle to
the DRG. Systemically delivered AAV9 may infect
sensory axons innervating skeletal muscle and thus are
transported to neurons within the DRG. Foust et al.
suggested the possibility that transport from muscle to
DRG occurs after systemic injection of AAV8 vector
[32]. Although the precise mechanism by which AAV9
vectors pass through the BNB is unclear currently,AAV9 vectors have a specific and favorable character for
the induction of RNAi in DRG.
With intraperitoneal administration of ssAAV9-
shRNA, we could not detect any substantial silencing
effect in the nervous system, except for in the DRG
neurons. Considering that we inhibited gene expression
only in DRG neurons, this method appears to have
potential for pain research. The study of pain is an
important area of biomedical research that is necessary
for the development of treatments for intractable pain.
Knockout animal models have produced remarkable
advances in the understanding of the mechanisms of
pain. Several molecules within DRG such as the δ-opioid
receptor [33]; the transient receptor potential (TRP) ion
channel family: TRPC, TRPV, TRPM, TRPA, TRPP, and
TRPML [34]; and the NR1 [35] and NR2B [36] subunits
of the N-methyl-D-aspartic acid receptor may work
together in the development of pain-related symptoms.
It has been suggested that the expression of some of
these molecules (e.g., TRPV1 and TRPA1) largely
overlaps various subsets of nociceptors and that these
molecules are functionally linked to and interact with
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silencing of multiple genes may be necessary to elucidate
the mechanism of individual molecules in noxious
sensation. However, it will lead to the embryonic lethal
phenotype when multiple genes are silenced in knockout
animal models. On the other hand, our method enables
to target plural genes by injecting ssAAV9-shRNA
vectors that silence different targets without any side
effects. The advantage of our method of gene silencing
is that it makes it possible to down-regulate multiple
genes at once to investigate the compensatory inter-
action of these genes while escaping from the embryonic
lethal phenotype of the genes.
Although we confirmed that the gene-silencing effect
in DRG lasted for as long as 3 months in our mice, we
did not examine the full duration of this silencing effect.
Prior exposure to the AAV capsid reportedly leads to the
activation of memory CD8+ T cells and results in the
elimination of AAV capsid-harboring cells and the
reduction of transgene expression [37]. However, these
reports all used human subjects, which are naturally
infected by AAV during childhood, and all experimental
animals other than humans have shown long-term
expression of the transgene after AAV-mediated gene
transfer [37]. In addition, unlike in adults, there are no
memory CD8+ T cells in the neonatal immune system.
Furthermore, we previously demonstrated that shRNA-
transgenic mice expressing the same shRNA used in the
present study showed marked significant suppression of
SOD1 for more than 1 year [38]. Considering these
combined results, we think that the ssAAV9-shSOD1
used in this report can stably achieve long-term suppres-
sion of target gene expression in DRG.
Conclusions
We succeeded in silencing target gene expression in
DRG after a single intraperitoneal injection of ssAAV9-
shSOD1 vectors without any adverse effects, such as
liver dysfunction, developmental abnormalities, and
sensory disturbance. Intraperitoneal injection of AAV9
will be examined in further studies for potential uses in
the development of treatments for diseases affecting
DRG neurons. DRG transduction may have potential
applications in models of chronic pain and other sensory
neuronopathies.
Methods
Construction, production, and titration of the ssAAV9-sh
SOD1 vector
We prepared the anti-SOD1 shRNA cassette as previ-
ously reported [39]. The anti-SOD1 shRNA cassette was
cloned downstream of polymerase III human U6 pro-
moter in the AAV vector plasmid (Stratagene, La Jolla,
CA, USA) (Figure 1). The silencing efficiency of theanti-SOD1 shRNA sequence was verified by using
several cultured cell lines and transgenic mice expressing
the anti-SOD1 shRNA, as previously described [38]. The
human growth hormone polyadenylation (hGH poly A)
cassette (Stratagene) was inserted downstream of the
shRNA sequence for the titration assay using qRT PCR
(Figure 1). The recombinant viral vector was produced
according to the three-plasmid transfection protocol by
using the calcium phosphate method as previously
reported [40]. AAV vectors were purified using ammo-
nium sulfate precipitation and iodixanol (Axis-Shield,
Norton, MA) continuous gradient centrifugation. Gen-
ome titers of the AAV vectors were determined by qRT-
PCR using the TaqMan system [41]. The following
primers and probes targeting the poly(A) signal were used:
5’-CAGGCTGGTCTCCAACTCCTC-3’ and 5’-GCAGTG
GTTCACGCCTGTAA-3’ served as the primer set, and
5’-TACCCACCTTGGCCTC-3’ served as the probe.
Animals
All of the animal procedures were performed in accord-
ance with the protocols approved by the Animal Experi-
ment Committee of Tokyo Medical and Dental University
(protocol nos., 0100101 and 0130113A). Imprinting
control region (ICR) mice were obtained from Oriental
Yeast Co. Ltd. (Tokyo, Japan). Postnatal day-1 ICR mice
were injected intraperitoneally with a volume of 200 μl
(1.0 × 1013 viral genomes/ml) of ssAAV9-shSOD1 vector
(n = 7). ssAAV9-GFP injected mice were used as the
control group (n = 7). The body weights of the mice were
measured throughout the experimental period. At 4 or
12 weeks after injection, all of the mice were euthanized
after performing rotarod tests and a series of sensory
behavioral tests. DRG, spinal cord and brain were
collected for analysis.
Measurement of RNA reduction by qRT-PCR
Total RNA was extracted from the collected tissues by
using Isogen (Nippon Gene, Toyama, Japan). DNase-
treated total RNA (0.2 μg) was reverse-transcribed by
using SuperScript III Reverse Transcriptase (Invitrogen,
Carlsbad, CA, USA). Complementary DNA (cDNA) was
amplified by means of the quantitative TaqMan system
on a Light Cycle 480 Real-Time PCR Instrument
(Roche) according to the manufacturer’s protocol. The
SOD1 mRNA expression level in each tissue was mea-
sured by using the following primers and probe: forward
primer, 5′-GGTGCAGGGAACCATCCA-3′; reverse pri-
mer, 5′-CCCATGCTGGCCTTCAGT-3′; and probe,
5′-AGGCAAGCGGTGAACCAGTTGTGTTG-3′. To
normalize the real-time PCR values, cDNA was also
amplified quantitatively with the TaqMan primers and
probe sets for glyceraldehyde 3-phosphate dehydrogenase
(GAPDH; Applied Biosystems, Warrington, UK). The
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expression level was calculated to estimate the shRNA
silencing efficiency. Significant differences between the
two groups were calculated with Welch’s t-test and signifi-
cance was defined as P < 0.05.
Western blotting
Proteins were extracted from DRG samples. The tissues
were homogenized in cold homogenization buffer
containing 0.1% sodium dodecylsulfate (SDS), 1%
sodium deoxycholate, 1% Triton X-100, and 1 mM
phenylmethylsulfonyl fluoride, together with a protein
inhibitor cocktail (Roche). A 4-μg aliquot of the protein
extracted from each sample was mixed with Laemmli
sample buffer (BioRad, Hercules, CA, USA), denatured
at 95°C for 5 min, and separated on a 15% SDS–PAGE
gel. The separated proteins were transferred to a polyvi-
nylidene difluoride membrane (BioRad) and incubated
with rabbit anti-SOD1 antibody (StressGen Biotechnolo-
gies, Victoria, British Columbia, Canada) and mouse
anti-GAPDH monoclonal antibody (Biodesign, Saco,
ME, USA) as the primary antibody. After incubation, the
membrane was rinsed and incubated with 0.1% horse-
radish peroxidase (HRP)–conjugated secondary anti-
bodies, goat anti-rabbit HRP IgG, and goat anti-mouse
HRP IgG (Thermo Science, Rockford, IL, USA). Pro-
tein–antibody interactions were visualized by using
Supersignal West Femto Maximum Sensitivity Substrate
(Thermo Science). The quantification of the band inten-
sity was measured by NIH Image J software (version
1.47). We calculated the relative expression levels and
performed the statistical analysis.
Pathological examinations
Mice were anesthetized and the perfused with PBS
followed by 4% paraformaldehyde. The DRG and spinal
cords were the dissected out, fixed again overnight at
4°C, and immersed in PBS containing 30% sucrose.
Thereafter, the specimens were placed in OCT compound
(Tissue-Tek, Sakura Finetek, Japan) and snap-frozen in
liquid-nitrogen, and tissue sections were cut to a thickness
of 10 μm with LEICA CM3050 S cryostat (Leica
Microsystems, Wetzlar, Germany) and mounted on glass
slides. DRG and spinal cord were stained with hema-
toxylin and eosin and Nissl staining. GFP was detected by
means of native fluorescence using LSM 510 (Carl Zeiss
MicroImaging GmbH, Göttingen, Germany). For immu-
nostaining with Iba1 and CD68, blocking of endogenous
peroxidase (1% H2O2 in PBS for 30 min), heat induced
epitope retrieval was applied. Sections were heated in
citrate buffer in a microwave oven at 100% power (700 W)
for 9 min, then left to cool down at room temperature.
After rinsing in ddH2O and PBS, sections were blocked in
10% Normal Goat Serum and incubated with polyclonalrabbit anti-Iba1 antibody (1:500, Proteintech) and mono-
clonal mouse anti-human CD68 antibody (Dako)
overnight at 4°C. The sections were then rinsed in PBS
and incubated with the horseradish peroxidase-labeled
polymer (N-Histofine Simple Stain MAXPO, Nichirei) for
1 h at room temperature. After rinsing again, the
immunohistochemical reactions was visualized using 3,3’-
diaminobenzidine tetroxide (DAB-4HCl, Dojin Kagaku).
The sections were then counterstained with hematoxylin.
Rotarod test
The rotarod test was performed by using an accelerating
rotarod (Ugo Basile Biological Research Apparatus,
Varese, Italy). The 12-week-old mice in both groups
were placed on the rod (diameter, 3 cm) in four trials
each day, for a series of 4 days. Each trial lasted a
maximum of 10 min; the time spent on the rod without
falling was recorded. The average time for each group
was calculated, and statistical significance was assessed
by one-way ANOVA with repeated measures. Signifi-
cance was defined as P < 0.05.
Sensory behavioral tests
The animals were placed in Plexiglas boxes (9.5 × 21 ×
25 cm) to become acclimated to the testing environment.
These boxes were then placed on an elevated perforated
plastic surface for at least 30 min before all behavioral tests
[42]. A blinded observer conducted the behavioral testing.
Tactile threshold
Mechanical sensitivity was measured by applying a series
of calibrated von Frey filaments (0.02–8 g) to the plantar
aspect of a hind paw. Each filament was applied once to
each mouse. Beginning with the 1-g filament, each
filament was applied perpendicularly to the hind paw for
4 to 6 sec. Brisk withdrawal of the hind paw indicated a
positive response, and a lack of withdrawal indicated
a negative response. This filament testing was repeated a
maximum of two additional times, and at least two
positive responses among the three applications of the
filament indicated an overall positive response. If the
mouse demonstrated an overall positive response, the
next lower force filament was applied as described
previously. If no overall positive response was observed
(zero or one response in three), the next greater force
filament was applied as described previously. Once the
crossover threshold could be determined (i.e., from
response to no response, or vice versa) the responses to
the next five filaments were recorded to determine the
median withdrawal threshold.
Response to acetone
By using a plastic tube connected to a 1-ml syringe and
without touching the skin, 100 μl of acetone was applied
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five times to each paw at an interval of at least 30 sec,
and the number of brisk foot withdrawals in response to
the acetone application was recorded.
Statistical analysis
All data are presented as means –standard error of mean
(SEM; n =7). We performed D’Agositino-Pearson nor-
mality test and confirmed a normal distribution for
performing parametric analyses. We performed the statis-
tical analysis by Student t test for comparisons between
the two groups for all experiments, with the exception of
the Rotarod test. For the Rotarod test, the average time of
each group was calculated, and statistical significance was
assessed by one-way ANOVA with repeated measures.
Significance was defined as p values less than 0.05.
Additional file
Additional file 1: Figure S1. Gene transfer to spinal cord after neonatal
intraperitoneal delivery. GFP expression was not detected except in the
posterior column and posterior horn (A) and there was no GFP
expression in the anterior side of the spinal cord (B). High magnification
views of boxed area in (A) was shown in (C). Arrow indicates the
posterior column and * indicates central canal. The nucleus of the spinal
cord was stained with DAPI.
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